02/19/2026
eHIV Review - Complimentary Issue
The newest chapter in PrEP is here.
Twice-yearly long-acting lenacapavir has been approved — and we’re breaking down exactly what clinicians need to know.
How does it compare to LA cabotegravir?
Who’s the right patient?
What monitoring is required?
What are the key safety considerations?
Join Matthew Spinelli, MD, MAS, for expert insights. https://buff.ly/wCfkEGS